IN THE CIRCUIT COURT OF THE CITY OF ST. LOUIS STATE OF MISSOURI The Honorable Timothy J. Boyer

JOHN	L. DURNELL,)		
)		
	Plaintiff,)		
VS.) Cause	No.	1922-CC00221
)		
MONSANTO COMPANY,)		
)		
	Defendant.)		

TRIAL TRANSCRIPT

Wednesday, October 18, 2023

Volume 11A

lunch was all right. I'm going to turn it over to Mr. Frazer for his cross-examination.

Mr. Frazer.

MR. FRAZER: May it please the Court. Good afternoon, ladies and gentlemen.

Good afternoon.

CROSS-EXAMINATION

BY MR. FRAZER:

- Q Good afternoon, Dr. Matasar.
- A Good afternoon.
- Q Dr. Matasar, in order for something to be a confounding factor, that confounding factor has to have an association with the disease; true?

A So there's different types of confounding factors. There are what we would call known confounding factor and unknown confounding. When you're identifying known confounding factors, those would be items that you know are associated with the outcome, either directly or indirectly. When you're conducting a case-control study, one of the challenges, of course, is that there may be unknown confounding factors that, by definition, can't be assessed.

Q A confounding factor has to be associated with the disease for it to be a confounding factor; true or false?

- A That's true.
- Q Thank you.

So any study that you've looked at, and you looked at a few of them, shared those with the jury, or that any scientist looks at, under your testimony, you don't even have to adjust for any pesticide confounding factors; true?

- A I don't understand your question.
- Q Well, you testified that pesticides don't cause non-Hodgkin's lymphoma; right?
 - A No, that wasn't my testimony.
- Q You testified that glyphosate doesn't cause non-Hodgkin's lymphoma?
 - A That was my testimony.
- Q You testified it doesn't matter if you wear personal protection equipment or not when you're using glyphosate; right?
 - A That was not my testimony.
- Q That's got to be, though, isn't it? There's nothing wrong to get it on your skin?
 - A I'm sorry. What's the question?
- Q There's nothing wrong, from your opinion, to get it on your skin; right?
- A My opinion is that the science tells us that exposure to glyphosate, or Roundup as its formulated

product, doesn't cause lymphoma.

Q And you've relied on an Agricultural Health Study, and you know that it was adjusted for confounding factors such as personal protective equipment; right?

A One of the assessments that was performed within the Agricultural Health Study was to look at what we call intensity weighting, which is to look at both exposure as well as whether or not personal protective equipment was being used and the types of ways that Roundup was being manipulated.

Q The scientists in the Agricultural Health
Study made an adjustment for those pesticide
professional applicators in Iowa and North Carolina as
to whether or not they wear personal protective
equipment; true or false?

A Yes, as contained within the intensity-weighted calculations. That was discussed.

Q So that the study that you're relying on, you, which you say don't even have to worry if people are wearing PPE with glyphosate, those scientists looked at it as a confounding factor; correct?

A They tested it as, one, to try to understand whether there is a relationship between total dose exposure and lymphoma and found none.

Q They called it a confounding factor, didn't

they?

2.1

A They assessed it as a confounding factor.

That was one of the calculations that they performed in order to test that hypothesis and found that, indeed, dose exposure didn't lead to an association with lymphoma.

Q What pesticide on the planet Earth, in your opinion, contributes or causes to non-Hodgkin's lymphoma?

A There be have a number of reports of pesticides that have done just that, medicines or chemicals such as 2,4-D, malathion, and dicamba, to name three that come off the top of my head.

Q Do you agree with all three of those that they can cause non-Hodgkin's lymphoma?

A While I haven't performed the same rigorous scientific assessment of those as I have here with glyphosate, I'm certainly aware of the scientific literature associated with exposure to those pesticides and the risk of lymphoma, yes.

Q Do you tell your non-Hodgkin's lymphoma patients when they've been exposed to those three pesticides that their non-Hodgkin's lymphoma is a cause of that exposure?

A If I ever had a patient ask me should I use

2,4-D, does that put me an increased risk of lymphoma, I would say that I haven't done a full scientific review, but I think it does, and I wouldn't use it unless you're confident that's not the case.

Q You had not done a full scientific review of glyphosate before lawyers came and hired you to be an expert witness; right?

You hadn't even done that, had you?

That's your own testimony. You had to take a deep dive. We all remember that.

- A That's true.
- Q So even -- so to prior to 2019, that's when lawyers came knocking on your door for Monsanto, the Hollingsworth Law Firm in Washington, D.C.

That's who contacted you; right?

- A I believe that was the name of the law firm, yes.
 - Q That's who you negotiated with; right?
 - A What do you mean "negotiated"?
- Q We'll look at your retention agreement. You negotiated with them, didn't you, sir?
- A I'll ask you again: What do you mean by negotiated?
 - Q You don't what the word "negotiate" means?
 - A I don't know how you mean it here, no.

Well, how does a treating oncologist, such as 1 Q yourself, use the word "negotiate" as a definitional or 2 3 useful word in your parlance? 4 I don't talk with my patients about 5 negotiating other than negotiating treatment decisions. 6 So that's my question. So you don't ever use 7 the word "negotiate" ever? This is the first time you've heard that word? 8 That's not what I said. 9 10 So what's your meaning of the word 11 "negotiate"? It's a pretty simple question. 12 Figuring out a plan, I guess. 13 3120. I hand you what's been marked as Plaintiff's Exhibit 3120. 14 15 Thank you. Α 16 Your signature's on the second page, isn't it, 17 sir? Yes, sir, such as it is. 18 Α 19 Is that your signature? 20 Yes, sir. Α 2.1 All right. Let's look at --Q 22 MR. FRAZER: Your Honor, I move this into 23 evidence. 24 THE COURT: Any objection? 25 MR. BROWN: Objection, your Honor.

hearsay.

THE COURT: Do you have a response to that?

MR. FRAZER: Your Honor, this is his retention agreement. This is the terms of how he came here to testify. He signed it. He's authenticated it. It's on the Monsanto law firm letterhead.

MR. BROWN: It's irrelevant to the facts of the case or the issues of the case, your Honor.

THE COURT: I'll admit the exhibit.

MR. BROWN: Thank you, your Honor.

MR. FRAZER: Thank you, your Honor.

Ed, let's pull up 3120. Let's look at the top of the page here. Go down and show his signature first so the jury can see that.

BY MR. FRAZER:

Q That's your signature right here, this little letter, kind of like Prince; right?

A That's why I said, "Such as it is." It's a doctor's signature.

Q It's a symbol; right?

A It's sort of like a stylized M and J. My middle initial is J.

Q Let's go to that second paragraph. It says you're going to get a minimum of \$3,000 for the full depositions in the New York area, and a rate to be

negotiated for depositions outside the New York area. 1 2 Negotiated; right? 3 That's what it says. Α 4 Q What did you negotiate for your testimony here 5 today? 6 As I said, my testimony today will be 7 reimbursed \$5,000 for today's work. 8 Q So you negotiated up from a minimum of \$3,000 to \$5,000 today; right? 9 10 Over these years I've had a change in Yeah. 11 my fee schedule. 12 Okay. Now, let's look at the first page of 13 this document. Second paragraph, please, Ed. Let's blow that 14 15 up. 16 It says you acknowledge that you have received 17 and/or likely will receive confidential information from 18 HLLP. 19 That's the Washington law firm; right? 20 I believe so. Α 2.1 And that you will likely -- you likely will 22 generate work product orally and/or in writing to assist HLLP in representing Monsanto in the litigation. 23 24 Do you see that? 25 Yes, sir. Α

Q Doesn't say anything about Bayer, does it?

A No, sir.

Q All right. Then the next sentence says you agree that you will maintain all information exchanged between HLLP and you, whether orally or in writing, as strictly confidential and privileged unless we inform you at some time in the future that certain information needs to be disclosed in the litigation; correct?

A Yes.

Q And then the next sentence says you also agree to maintain the fact that you have been retained by HLLP as strictly confidential and privileged unless we inform you at some time in the future that your identity as HLLP's expert has been disclosed this litigation; true?

A Yes.

Q Now, you told the jury you told your patients that you signed this letter, that you tell them you're working for Monsanto.

Is that what I heard you say?

A What I said, to be clear, is that I'm involved with these cases and I've been involved as an expert, yes.

Q So you disclosed information to your patients that you agreed to keep strictly confidential and privileged; right?

A I've never talked to my patients about this law firm.

Q Okay. Then the next paragraph:

"Furthermore, you agree to not do any consulting or other work for any other corporation, law firm, or person with respect to any actual or potential legal claims involving Roundup and/or glyphosate."

Did I read that right?

- A Yes.
- Q You cut an exclusive deal, you negotiated an exclusive deal with Monsanto's lawyers here; right?
 - A That was the agreement at the time, yes.
- Q So you can't even work for somebody like John Durnell. You can't even work for one of your patients; right?
 - A I'm here to do the work with you here today.
- Q You cannot go work for one of your patients who comes in and says, "I think I got my non-Hodgkin's lymphoma from Roundup and I want to hire you as an expert."

You'd have to tell me no; right?

A The first thing I would tell them is that I don't think that Roundup caused their lymphoma.

But yes, if they were trying to hire me as a legal consultant, I would have to say that I'm not

available to do that work for them. 1 2 You'd have to tell them no; right? 3 Just what I just said, that I'm not able to do Α 4 that legal consulting working, yes. 5 If there was a group of people that wanted you 6 to do research on non-Hodgkin's lymphoma and Roundup 7 exposure, you'd have to tell them no; correct? I'm not sure. 8 9 You're not sure. 10 You gave a deposition in this case on July the 11 24th, 2023, just a few months ago; right? 12 Α I believe that was the date. 13 And have you looked at that deposition? 14 Α I reviewed the transcript afterwards, yes. 15 And it's fair to say you didn't make a written Q 16 report in this case? 17 Α I believe so, no. You've done that in other cases? 18 0 19 That's true. Α 20 You did it in a case called Marty Hay, Daniel 0 2.1 Anderson, Jimmy Draeger, and Valorie Gunther v. Monsanto 22 filed in Cole County, Missouri; right? MR. BROWN: Your Honor, can we just briefly 23 24 approach? 25 (Counsel approached the bench and the

following proceedings were had:)

MR. BROWN: I didn't want to stop his flow, but if he can not mention the specific case names involving other cases, I'd appreciate that.

There's no need to put that in the public record.

THE COURT: Is there any relevance of why you're mentioning specific case names?

MR. FRAZER: Well, you're going to see, because I'm going to direct him to what he said in that deposition in that case. Absolutely.

THE COURT: But you don't need to mention the specific case name to impeach him with a deposition; correct. If you're setting up an impeachment, then set up the impeachment and impeach him.

MR. FRAZER: I've always been taught to do that. But if you don't want me to.

THE COURT: It comes up and it becomes relevant, I'll let you do what, but if we're just impeaching him, set up the impeachment and then do it.

(Proceedings resumed in open court.)
BY MR. FRAZER:

- Q You remember that Cole County, Missouri, case?
- A You said it's the case of Mr. Anderson?

1 Q Yes. 2 Yes, sir. Α 3 You made a written report in that case, didn't Q you? 4 5 Α I did, yes. 6 Q You gave a deposition in that case, didn't 7 you? 8 Α Yes. 9 Q That deposition is given on -- do you remember 10 the day? 11 Α I don't. 12 Do you remember the date? 13 Α I do not. 14 Do you know it was given after you gave the deposition in Mr. Durnell's case? 15 16 Α I believe so. 17 In that deposition you were asked by the lawyers what other cases have you given deposition 18 testimony in. You didn't mention the Durnell case, did 19 20 you? 21 I don't remember. Α 22 Do you want to see your testimony? Q 23 Α If you want me to look at it, I'm glad to. 24 Sure. Q 25 Α I believe you.

- This was an all-day deposition too, wasn't it? 1 Q 2 It was a long day. Α 3 Can you help direct me where I'm looking in 4 the document, please, sir? 5 Yes, sir. I'll be glad to. 6 Α Thank you. 7 0 If you go to page 9, line 6 through 13. 8 Α Page 9, you said. Thank you. 9 Q The deposition page 9. 10 That's the one on the right-hand side. Α 11 I don't know if that's the Min-U-Script or --0 12 Thank you. Α 13 Nine? Thank you. Can I take a moment? 14 Α 15 You were asked: 0 16 "Since June and your provision of these 17 materials, have you been deposed in any other 18 matter?" 19 "ANSWER: I'll admit that I don't keep track 20 very well of my calendar, but there's been no 2.1 matters unrelated to Monsanto for which I've
 - Whatever the name of that case is.

taken a deposition since the" --

A Yes.

22

23

24

25

Q And you identified seven depositions that did

1 2

involve Monsanto, and none of them were the Durnell case; right?

MR. BROWN: Objection, your Honor. Misstates what the testimony is of the witness. It says matters unrelated to Monsanto.

BY MR. FRAZER:

Q You didn't identify the Durnell case as a case you've given a deposition in, did you, sir?

A In reviewing the transcript from the deposition, when I was asked if I had been deposed, my answer was, "I'm not certain."

- Q Not certain?
- A Yeah.
- Q Okay. That's fine. We're done with that one.

You mentioned that your -- the center that you work for at right now, Rutgers, was an NCI-certified cancer center?

A NCI-designated cancer, comprehensive cancer center.

Q Did you know that there's an NCI-designated comprehensive cancer center at Wash U. here in St. Louis called the Siteman Center?

- A I'm very familiar.
- Q All right. And they have oncologists just like you at Siteman Center?

It has a very well-established oncology 1 Α 2 program at Siteman as well, yes. 3 But Monsanto had to go all the way to New York 4 to get you for this case; right? 5 I don't know how to answer that question. 6 Q Well, you live in New York; right? 7 Α I do. You don't live here in St. Louis? 8 Q 9 Α I do not. 10 You've never practiced medicine here at the Q 11 Siteman Center? 12 Α No, sir. 13 Have you seen any Monsanto documents that indicate that Monsanto knows doctors at the Siteman 14 15 Center here or at Wash U.? 16 I haven't been shown any documents yea or nay. Α 17 Now, since you've given eight depositions 18 before -- is it eight or have you given a ninth one 19 since your last one? 20 I do not keep track of that number. 2.1 You don't know? 22 Α Correct. 23 By the way, you get your 1099 on compensation, 24 you get it from a law firm, not Monsanto; right?

I believe so, yes.

25

Α

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

25

A 1099 is something that shows your outside Q independent contractor income for a particular year; right?

That sounds right.

So you've given at least eight depositions on this matter, maybe more is what your testimony is. just don't know?

My testimony is I don't know the number. That's right.

It's the first time you've testified live in front of a jury, though; right?

Α Very true.

But you will agree with me that Monsanto already knew what you were going to say under oath before you came in the door today; right?

I don't know what Monsanto knows or doesn't Α know about me, but my opinion in the matter, I've been clear about my interpretation of the science and the conclusions I've reached.

Well, has the lawyer from the Hollingsworth firm written and you said, "Hey, we don't like what you're saying"?

Α I haven't spoken with that lawyer in some time either way, but certainly not.

Any lawyers from Monsanto call you and say you

1 | need to change your testimony?

A They've never said that it's good or bad. I'm here as an expert to share my expertise.

Q To borrow your phrase, when you stepped into that chair today, Monsanto knew it was not rolling the dice with you; correct?

MR. BROWN: Objection. Misstates the witness's testimony, your Honor.

THE COURT: I don't think it misstates his testimony. I'll let him answer if he has an answer.

THE WITNESS: I'm here to tell the truth and share my understanding of the science, and that's what I've done today.

BY MR. FRAZER:

Q Monsanto knew what the dice were going to show when they put up on the stand here today; right?

A I don't know what they knew, but certainly, as I've said, my opinion on the science and the conclusions that I've drawn are very clear and consistent.

Q Well, you rehearsed your testimony before you took the stand today, didn't you, sir?

A I did not rehearse the testimony, but we certainly went through this process. As I said this is new to me. I worked with attorneys on preparing for

today certainly.

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

25

- Q Yeah, you had 56 slides by my count; right?
- A I'll trust your number.
- Q Huh?
- A I trust your number.
- Q That would take a while to go through with a bunch of lawyers about your upcoming testimony; correct?
 - A We spent some time on it, yes.
- Q Okay. So Monsanto went to the East Coast to get you, and they went to the West Coast to get Dr. Tomasetti; right?
- A Nobody ever flew out to get me. I have just been involved in these matters.
- Q Well, you flew in here. You didn't drive to St. Louis, did you?
 - A That's true.
- Q Okay. And my understanding is that this was your first retention date, March 25, 2019, as shown on Plaintiff's Exhibit 3120; right?
 - A I believe that's true.
- Q You had some conversation before that day with that lawyer from Washington, D.C.; right?
- A I don't remember where that attorney was from but, yeah, there were conversations that preceded my agreeing to work in these matters.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Were you with multiple lawyers for Monsanto Q before you agreed to this letter?

It was just one attorney that I had spoken to before that.

All right. And over the course of the last four and a half years, how many lawyers for Monsanto have you worked with?

I couldn't tell you a precise number, but somewhere in the -- I guess the five to ten range would be my guess.

Five to ten range. All right.

So the -- and, as I understand it, before March 25, 2019, you had really never studied glyphosate; right?

I hadn't done this rigorous scientific assessment of glyphosate that I've gone through with you today, but certainly, as I said, I was aware of it both in and of itself and in the context of this preceding scientific understanding of pesticides in general and their potential relationship to lymphoma.

- You've never published a paper on glyphosate?
- Is that a question? Α
- Prior to March 25, 2019, never published a paper on glyphosate?

No, sir. Α

Prior to March 25, 2019, you never published a 1 Q 2 paper on Roundup? 3 That's also true. 4 Prior to March 25, 2019, you hadn't looked at 5 any of the studies; right? 6 Α That's not true. 7 0 Not true. 8 You do know what IARC is; right? 9 Α Yes, sir. 10 Had you looked at that one before March 25, Q 2019? 11 12 I was aware of it, although I hadn't read the Α 13 full monograph prior to this. 14 You hadn't read the full monograph? 15 Α No, sir. 16 What studies have you looked at before March 17 25, 2019? 18 I'm not sure -- I'm not certain that I can 19 quote which studies I had looked at at that point. 20 Dr. Tomasetti yesterday referred to IARC as 2.1 the gold standard. 22 Do you agree with that? 23 Α The gold standard with regards to what? 24 The study of cancer. Q 25 There is no single gold standard for the study Α

of cancer. That's overly broad. They're certainly an important agency for doing hazard assessments, but as an oncologist, treating my patients, I don't turn to IARC to understand their illnesses or the treatment plans for my patients.

- Q You've never been invited to participate in a IARC working group, have you, sir?
 - A No, sir.

- Q You know Kristan Aronson, Dr. Aronson has; correct?
 - A I believe.
- Q You've never given a lecture on glyphosate or Roundup in your life; right?
 - A No, sir.
- Q Did the lawyer who called you say how they came to know to even give you a call?
- A I didn't ask. I presumed that it was on the basis of my being an established expert in lymphoma.
- Q I mean, we can see why Monsanto would call Dr. Tomasetti. But there was nothing in your published works or your lectures that had anything to do with Roundup, glyphosate at all; right?
- A And yet there's only so many people in the world that do what I do, that have a focused clinical and scientific emphasis specifically on lymphoma.

- 2.1
- Q We're going to look at your papers in a minute. Your papers have been focused on therapy and treatment; correct?
 - A Not exclusively, no.
 - Q Okay. We'll go through them.

I'm just saying, how would somebody, a lawyer out there doing research, find out, if we should give an oncologist a call, how would they know to call you?

MR. BROWN: Objection. Calls for speculation, your Honor.

THE COURT: I agree. I'll sustain the objection.

BY MR. FRAZER:

- Q Did any of these lawyers tell you how they picked you out of the crowd?
- A I wouldn't say there's a big crowd of lymphoma experts. No, I don't know why I was asked to begin doing this work.
- Q Well, there are lymphoma experts right here in St. Louis; right?
 - A Yes.
- Q There are doctors here in St. Louis that do exactly what you do every day; right?
 - A There are lymphoma experts here definitely.
 - Q And at least 48 other National Cancer

Institute-designated sites or centers; right?

A I don't know if every center has an established lymphoma program. But, yeah, there are many excellent cancer institutes in this country.

Q Okay. At your deposition, you said you were up to about a total of \$20,000 in compensation in the Durnell case. Would that be fair to say that in the other eight cases you've testified you're about at that number too?

A I'm not sure. Some have taken more time and some less, but probably all similar, within range.

Q And then you top it off with whatever you charge for traveling here?

A Yeah, I'm submitting invoices for my travel time here.

- Q For your meeting time with the lawyers?
- A Yes.

2.1

- Q Or phone calls?
- A Work that I'm doing on this case, yes.
- O or texts?
- A No. I wouldn't know how to track that.
- Q Okay. We had an expert here talk about texting with the lawyers. That's why I asked you.
 - A Maybe more organized than I am.
 - Q And you and Dr. Tomasetti have worked together

1 on these cases; right?

- A I've never met Dr. Tomasetti.
- Q Wasn't my question.

You know he's an expert in some of these other cases that you're an expert for Monsanto in; right?

A I know he's doing -- I know he's participating in these cases, but we don't work together. We've never even met one another. There's no teamwork there.

Q Now -- no teamwork. Okay.

Okay. You've never published on Dr.

Tomasetti's bad luck theory; right?

A I wouldn't say it's a bad luck theory, but no, I've never published any papers critiquing Dr.

Tomasetti's work.

Q Well, bad luck is what Dr. Tomasetti testified that he calls it.

A If those are his words, those are his words, but that's now how I would characterize the science at all.

- Q Have you read his papers?
- A Which papers are you -- if you are speaking specifically to the ones regarding random replicative error, then yes.
- Q Did you read the one that he calls it the bad luck theory?

If that's the word used in the paper, I don't 1 Α 2 remember that. I'm certainly aware of the underlying 3 scientific principles. 4 Q Do you use that word with your patients: You 5 got non-Hodgkin's lymphoma and it's just bad luck for 6 you? 7 I don't say those words to my patients. Okay. Good. That's good to hear. 8 Q His article that was published in 2015 is 9 10 literally just a three-page article, isn't it? 11 I don't remember the length of it, but it's 12 possible. 13 Do you want to take a look at it? 14 Α If you want me to. 15 All right. Q 16 MR. FRAZER: It was introduced into evidence 17 as D1, your Honor. Is that still up here? 18 THE COURT: Somewhere. 19 MR. FRAZER: Well, we can do it on the screen. 20 That's fine. 2.1 THE COURT: No, that's not it. 22 BY MR. FRAZER: 23 That's the cover of Science magazine; right? 24 One of the most preeminent scientific journals

25

in the world.

I thought you would add that. The top of the 1 Q 2 thing says, "Are most human cancers due to bad luck"; 3 right? 4 That's what it says on the cover. 5 0 And if we turn the page, you see there's print 6 from another article on this page; right? 7 Yeah, that's how it done. 8 0 Let's look at the second page. Then we got a 9 big old chart that Dr. Tomasetti edited yesterday. 10 Do you see that? 11 I see the chart on the page here, yes. 12 And then we turn the next page, and we got a 0 13 chart, and that's where the reference notes start; 14 right? 15 Yes, sir. Α 16 That's three pages? 17 Α In addition to references. And I don't 18 remember whether this article had any appendices or 19 supplementary materials. 20 This article was published in Science magazine 2.1 the way it's published right here. 22 Do you understand that, sir? You're showing me the paper. Of course. 23 Α 24 Pardon me? 0 25 Α You're showing me the paper. Yes.

This is what the lawyers that hired you put 1 Q 2 into evidence. Not me. Okay? 3 Do you understand that. I'm not trying to 4 trick you or anything. 5 I'm not sure I understand the question --6 Q If you take out the charts --7 MR. BROWN: Your Honor, could the witness see 8 the article? 9 THE COURT: I got it somewhere. 10 It's D1 in this book. 11 THE WITNESS: I'm sorry, which one? 12 THE COURT: D1 in this book. 13 THE WITNESS: Thank you, sir. MR. BROWN: I was going to ask for one for me 14 15 too, but I guess not. 16 MR. FRAZER: It's y'all's exhibit. 17 THE WITNESS: Yes. 18 BY MR. FRAZER: 19 Do you see anything there that you want to 20 change your testimony on that we just talked about? 2.1 Α No, sir. 22 Okay. Thank you. Q 23 Now, that article was published in 2015; 24 right? 25 That's correct. Α

And did -- and the publication date, if we 1 Q 2 look at the cover, was January 2nd, 2015; right? 3 Yes. 4 That article was published before IARC met in 5 March 2015; right? I don't remember whether that was the date 6 7 that IARC met or the publication date, but, yes, January 8 2nd, 2015. 9 Every scientist that would be working on 10 anything that had to do with anything that was in that 11 article would know about that article before March of 12 2015; right? 13 That I can't tell you. 14 Q Did you read the article back then? 15 At that time, no, I don't remember reading it Α 16 then. 17 When's the first time you read it? 18 I'm not sure. Α 19 After you met with the lawyers from Monsanto? Q 20 Α Yes. 2.1 So that was 2019; right? Q 22 Yes, sir. Α 23 So over four years later is the first time you 24 even knew about this article by Dr. Tomasetti, Exhibit 25 D1?

I wasn't aware of it beforehand. That's true. 1 Α MR. BROWN: Objection. Mischaracterizes the 2 3 witness's testimony. 4 THE COURT: I think he's answered it as best 5 he can. 6 MR. BROWN: I'm good, Judge. 7 MR. FRAZER: Yeah. 8 BY MR. FRAZER: 9 So prior to that time, you weren't telling any of your patients that their non-Hodgkin's lymphoma was 10 11 due to replication errors; right? 12 That's not true. 13 Not true. 14 Okay. Do you have any patient records to 15 share that would have the personal information redacted 16 out that shows if you actually put it in their records? 17 MR. BROWN: Your Honor, objection. Patient records are confidential and cannot be described in 18 19 this lawsuit. 20 MR. FRAZER: I'm just asking him. 2.1 THE COURT: You're asking him for something he 22 can't produce, so I'll sustain the objection. 23 BY MR. FRAZER: 24 You produce medical records all the time, 25 don't you, sir?

Can you tell me what you mean? I don't 1 Α 2 understand. 3 You saw Mr. Durnell's medical records in this 4 case. You testified to that to the jury, didn't you? Yes, I reviewed his medical records. 5 6 You've reviewed medical records of other 7 victims that claim that glyphosate or Roundup caused 8 their cancer; right? 9 MR. BROWN: Objection to the use of word 10 "victim." Inflammatory, your Honor. THE COURT: I'll let him answer the question 11 12 if he has an answer. 13 THE WITNESS: I wouldn't characterize them as victims, but, yes, I've reviewed other patients' 14 15 medical records, both in these Roundup cases as 16 well as part of my practice as a lymphoma expert. BY MR. FRAZER: 17 18 All right. You've gotten research funding 19 from Bayer, haven't you? 20 Yes, I've conducted clinical trials using 2.1 pharmaceuticals that are made by Bayer in the treatment 22 of lymphoma. 23 0 Pharmaceuticals? 24 Medicines, yes. Α

In the treatment?

25

- 1 Α Of lymphoma, yes, sir. 2 And you also have individual stock and stock Q 3 4 Α onto them out of sentimentality. 5 6 7 8 9
 - options with a company called Merck? I inherited those from my grandmother and hold
 - First of all, I'm really sympathetic to cancer victims, so I'm so sorry you had to go through cancer.
 - Thank you. That's very kind of you.
 - I know what it's like. And, you know, thank you for sharing that with everybody.

But the cancer you had was -- was it renal cancer?

- Α Correct. Kidney cancer.
- Kidney cancer? 0
- Α Yes.

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

25

- Doctors call that renal carcinomas? 0
- Α Renal cell carcinoma. Correct.
- Have you seen the Knezevich and Hogan study that Monsanto paid for that showed tumors in the kidneys of mice?
- I'm not sure if I can quote that individual study, but I've reviewed extensive animal studies about Roundup, yes.
- Do you see in the Knezevich and Hogan case study that the tumor incidence was 640 percent higher

1 | than the control group?

A I don't remember that specific -- that single statistic here, no.

- Q How old --
- A I'm sorry. I couldn't hear you.
- Q I have a bad habit of doing that. I apologize.
 - A No problem.
- Q How would a man were you when you got kidney cancer?
- A Let me do the math. My daughter was nine months old, and she's now 17. So 17 years ago. It's now 2023. So about 32, give or take.
 - Q 32 years old?
 - A Ballpark.
- Q And is it fair to say for the record that you're at that time at 32, and I think you probably still are, because look how old I am, but at 32 you were a young white male?
 - A Definitely. Certainly younger than I am now.
- Q Yeah. And you've had -- you testified in your deposition that you actually used Roundup when you were a child; right?
 - A A little bit, yes.
 - O A little bit?

- A Yeah, I remember using it some summers at my home in Michigan.
 - Q Have you ever looked at a warning label on Roundup?
 - A Not that I remember.
 - Q Do you know how much you used it as a child?
 - A No.

2.1

- Q Have you ever consulted with a Ph.D. named Dr. Robert Tarone?
 - A Consulted with?
 - Q Yeah. Do you know who he is?
 - A No, I don't recognize the name.
 - Q Don't recognize the name.
- In all the NHL studies you've done, you haven't seen his name?
- A Maybe I'm not so great with names, but I don't remember it, sitting here.
- Q Okay. Are you familiar with Dr. Tomasetti's Planet B hypothetical?
- A Yes, I'm familiar with the way that he tried to describe some of these underlying issues of random replication in his manuscripts.
- Q Would you and Dr. Tomasetti together, and I understand you haven't gone together anywhere, but have you personally gone to the EPA and said, "Just cut out

25

all the research on glyphosate and whether or not it causes cancer because it's all due to replication

Have you done that?

- No, sir.
- You haven't said, "Hey, we can say a lot of taxpayer dollars if we just cut out all this research because in my opinion, Dr. Matasar, there's no way NHL is caused by exposure to glyphosate"?
 - I'm sorry; what was the question?
 - Have you ever done that?
 - Done?
- Gone to the EPA and say, "Hey, you can save a lot of money here. Just cut out all the research requiring companies or anybody or scientists or the EPA to study human health and exposure to glyphosate."
 - No, sir.
- You haven't written a letter to IARC like that; right?
 - No, sir.
- Or any other cancer institute in the world;
- I've never written a letter to people telling them that, no.
 - You mentioned New Zealand earlier and

Australia. Have you written any letters to them,
saying, "Hey, you guys need to quit studying human
health and exposure to glyphosate because, in my
opinion, there's no way it's caused by exposure to

qlyphosate"?

2.1

A I'm not sure what research they're still conducting, if any, but no, I've never written such a letter.

Q You didn't write that to the Canada folks either, did you?

A I've written no such letter.

Q Do you have any idea who was on the IARC panel that made the decision in Monograph 112 that glyphosate was a probable human carcinogen?

A I can't name members of the IARC panel off the top of my head, but certainly reviewed their author list in reviewing the monograph.

Q Do you know one of them was Aaron Blair? He was the chairman of the group.

A I believe you.

Q He was the one that wrote the Agricultural Health Study; right?

A What do you mean wrote the Agricultural Health Study?

Q He was one of the authors.

- 2.1

- A That's possible.
- Q That's not possible, it's true, isn't it?
- A I would need to review the authors list of the AHS manuscript, but I believe you.
- Q And by the way, the Agricultural Health Study, AHS, is not some monolithic study. It's a monolithic database; right?
- A No. It's a monolithic research program. It's a prospective cohort study enrolling many individuals over time and follow their health outcomes. There's lots of different analyses being done in the context of that cohort study, but it is a research program.
- Q As I understand it, Dr. Blair, Dr. Andreotti took the data that was in the study and then published the article that you're relying on.
- A One of the articles that I shared with you today, yes.
 - Q The only one that talked about AHS; right?
- A There were two. There was the original 2005 report from the AHS and the updated results that Andreotti and his colleagues published. These are not the only papers that I've shared with you today.
- Q And the updated results were published in November 9, 2017; right?
 - A I have it as 2018, so I would need to see the

manuscript.

2.1

- Q Well, let's pull it up. It's Defense Exhibit 24.
 - A Thank you, sir.
- Q I think you can see the date published there up in the top right.
- A Published online, yes, but its official publication date is 2018, yes.
- Q And the title of it is "Glyphosate Use and Cancer Incidence in the Agricultural Health Study"; right?
 - A Yes, that's the title.
- Q It's not "Roundup Use and Cancer Incidence in the Agricultural Health Study"; right?
 - A The title is glyphosate, yes.
- Q In fact, if you want to take the time, but I'll represent to you that the word "Roundup" doesn't even appear in this article.
 - A The word "Roundup" is not in the article.
- Q Okay. I just want to be sure. Because you kept saying Roundup, and it only talks about glyphosate; right?
- A I used the word "Roundup" because this is a study of actual agricultural workers that are using formulated product and following their health outcomes.

That's why Roundup for me is the better term than just talking about the individual chemical glyphosate.

Q Let's look at the second page of the study that you're relying on at the top of the left-hand corner page. It says, "As of 2010, more than 750 products containing glyphosate were on the U.S. market"; right?

A I see that line, yes.

- Q Did you know that there were 20 companies in the glyphosate task force group?
 - A No, I don't know that task force group.
- Q Do you think they all make their glyphosate herbicide the same way as Monsanto makes Roundup? Do you think they're identical?
 - A I don't know.
 - You don't know. That's the point, isn't it?
 You don't know?
 - A That's what I said, yes.
- Q So in this study that you're relying on, there's no confounding factor taken into consideration for what kind of glyphosate-based herbicide any of these professional licensed applicators from North Carolina and Iowa were using; correct?
- A That's not how I would use the word "confounding."

It's not in there. It doesn't account for it? 1 Q 2 Yes, this is pooled glyphosate use. Correct. Α 3 So if some other company's glyphosate-based 4 herbicide had different things in it or different things 5 not in it than Monsanto's Roundup, that might skew the 6 results one way or the other; right? 7 And yet the results are what they are, which 8 is that there's no increased risk of lymphoma for users of formulated glyphosate products. 9 10 If you got 19 out of 20 companies making 11 glyphosate-based herbicides with over 700 products and 12 you haven't figured out which farmer used what product, 13 you really don't know; right? And yet there's still no increased risk of 14 15 lymphoma. That's the bottom line. 16 Well, let's look at that. 0 17 But you don't know the answer to that question I just asked you? 18 19 What was the question? 20 Are you just trying to -- did you have a 2.1 course in blocking and bridging, by the way? 22 MR. BROWN: Objection. 23 THE COURT: Sustained. 24 BY MR. FRAZER: 25 Would you answer that question?

2 3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23 24

25

Could you repeat the question for me, please, Α sir?

The question is 19 out of the 20 companies, you don't know what's in their formula -- you don't even know what's in formulated Roundup; right?

Not to any specific degree; correct.

So you can't make an apples-to-apples comparison inside the Agricultural Health Study database at all because you don't know what farmer in Iowa used what glyphosate-based herbicide versus a farmer in North Carolina, what that person used; right?

And yet the data are the data and it's shows Α that users of these formulated products aren't at increased risk for lymphoma, period.

The formulated products.

But if you had higher incidence in this study with farmers that used Roundup, and you had lower incidence in farmers that used 19 of the other companies' products, because they were made differently, you couldn't -- it would skew the study one way downward; right?

You'd still expect to see a signal, and there is no signal.

And there's no quantification in here what the percentage of glyphosate in all those products was used

1 by all these farmers; right?

A Not that I'm aware of, no. There is this intensity modulation that they performed to try to get at that underlying truth regarding dose and exposure.

Q And you said you read Mr. Durnell's deposition. The ladies and gentlemen heard his testimony. He's never been a farmer in his life, has he?

A No, sir.

Q In this Agricultural Health Study article that you're relying on, D24, it says there was 7,290 incident cancer cases; right?

A Can you show me where you're reading?

Q The second page, right here, bottom of the first big-ole paragraph.

Next-to-the-last sentence.

A I got you. Yes, sir.

Q 7,290; right?

A Yes.

Q Now, you know, you put that -- did you put the 55,000 number up on the board.

Do you remembered that?

A I remember the numbers I presented, yes.

Q I don't know if you had it exact or rounded up, but I recall it was about 55,000 people in this

study. 1 2 Just over. 3 What was the dropout rate? 4 Α In terms of completed the data throughout the 5 two-decade period? 6 Q Yes, sir. 7 Approximately 40 percent. 8 It was 46 percent, wasn't it? I'd have to review the data to find the 9 10 precise number, but approximately 40 percent. 11 Well, let's look at the study. I want to get 12 the study to get it straight. You're relying on it. 13 You should know. Thank you, sir. 14 15 Keep the AHS study. We're not finished with 16 that that one. 17 Α Okay. The Andreotti study. That's really what it's 18 19 called, the Andreotti? 20 No, sir. Α 21 No? 0

I thought you called these studies by the last name of the first listed author.

A Individual manuscripts do, not the overall research program.

22

23

24

1 Q Excuse me. 2 THE COURT: Mr. Frazer, I don't see it marked 3 on this. Is this a marked exhibit? 4 MR. FRAZER: No, no. This is just for refresh 5 his memory. 6 BY MR. FRAZER: 7 Do you see right here that these scientists 8 are writing about assessing the potential for bias from 9 nonresponse --10 Are we on --11 -- to a study follow-up interview and example Q 12 from the Agricultural Health Study? 13 Α We're on this other page. Pardon me. 14 Q Do you see that? 15 Hold on one second. Α 16 Yes, I see that. 17 It's dated after the Andreotti article; right? Q This predates the 2018 manuscript. 18 Α No. 19 2018? Q 20 Yes. This was published July 7th, 2017, and Α 2.1 the paper by Andreotti and colleagues was published in 22 November of 2017. 23 So Andreotti and all the people that wrote 24 paper would have had the benefit of what's in this

25

paper; right?

- 1
- Α
- I couldn't answer that yea or nay.
- 2
- Q
- Well, it happened before then; right?

- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25

- Yes, but whether they were aware of it, I Α don't know.
- It involves the Agricultural Health Study; right?
 - It uses that as an example, yes.
- Q And in the -- at the top it says the Agricultural Health Study involved 52,394 farmers in 1993, '97 -- wait a minute, yeah -- and collected additional information during subsequent interviews.
- 46 percent of enrolled farmers responded to the 2005, 2010 interview; right?
 - I see that.
 - So actually 54 percent dropped out.
- For that one interview, that was their Α response rate for that one interview, yes.
- Well, you know there's a true even to today. They can't find those people.
 - You're the AHS expert.
 - Sorry. What was your question, sir? Α
- You know that those people that were in the original AHS study, 54 percent, half dropped out of the study, and the database is less 54 percent times 53,494; right?

2.1

_

A I don't have access to the updates in terms of loss to follow-up. And yet every cohort study will always have incomplete data. And the authors of the Agricultural Health Study worked very hard at both reporting that and performing additional analyses to account for those.

Q In the very next phrase after the semicolon it says 7 percent of the farmers died prior to the interview.

Right?

- A It says that, yes.
- Q 7 percent times 50,000 is what?
- A Do I need to take out my calculator?
- Q 3500?
- A Ballpark.
- Q 3500 farmers had died. You can't follow people that are dead; right?

A They still inform the ultimate analysis because you have their medical records. They're involved with health registries, so you know what their unfortunate cause of death was to help inform the results of the study.

- Q You cannot follow a dead person; right?
- A No. Once somebody has died, they're no longer being followed continuously, but they're still included

2.1

22

23

24

25

the study and assessed as part of the study.

Q And nobody knows what the health condition was of this 54 percent of farmers that couldn't be reached?

A As I've said, every cohort study will have loss to follow-up. That's true. That's the nature of those studies. Just as with case-control studies, you'll have incomplete participation rates of people that you call to invite into the study.

Q Some of those farmers could have moved close to a cancer center; right?

A Sure.

Q And, in fact, if we look at the results page, 397, on that same document.

- A We're still in the paper by Rinsky?
- Q Yes, sir.
- A And which page, sir? I apologize.
- Q The results page.
- A Thank you.

Yes, sir.

Q It says in total 24,171 farmers responded to the 2005 2010 interview and 28,223 farmers did not.

Right?

- A Including the ones who had passed away, yes.
- Q And it said nonrespondents included the farmers who died prior to the interview?

A Yes, sir.

2

3

Q And if we turn the page, we actually have a table that points that out; right?

4

A Yes, sir. I see Table 1.

5

6

Q Okay. Now, let's go back to the Agricultural Health Study. Nowhere in this study that postdates that study do they say they were any dropouts; right?

7

A I don't believe that's true.

9

Q Well, find it for me. I don't see it in the text.

10

A May I take a moment?

12

11

Q Sure.

13

A Thank you, sir.

14

Yeah, so it's presented on my -- on what my document is page D24.4.

1516

Q D24.4. Where are you? I want to find it.

17

A In the paragraph beginning with the words, "In

18

19

Q Right.

primary analyses."

20

A So later on down that paragraph you see, "To evaluate the impact of using imputed exposure data for

2122

participants who did not complete the follow-up

participants who completed both questionnaires."

23

questionnaire, we limited the analysis to the 34,698

24

25

And then they made a mathematical projection

1 bas

based on what they thought the people who had been lost in the study would say if they weren't lost; right?

A So the authors of the Agricultural Health Study performed two different tests to account for or manage this predictable loss to follow-up.

The first is what is called imputation, which is acknowledging that you have incomplete data and using substitutive sources of data to give best estimates.

The second is they restricted their analysis to only those patients for whom they had responses as a way to quality test the strength and reliability of those results.

Q This study took the 54 percent of the people that didn't respond and projected what they would have said under some kind of mathematical model; right?

A As I said, they did two separate analyses.

Q Yes or no, and then you can explain.

A Yes. That was one of the ways they assessed for that.

Q Thank you.

Now, you see Table 2 in this Agricultural Health Study that's Exhibit 24?

A Table 2, yes, sir.

Q We can agree that mantle cell lymphoma is not even on here; right? They didn't look at that.

A The words "mantle cell lymphoma" are not included in this table, no.

Q There are a lot of -- I know you don't like the word blood cancers, but there are blood cancers in here; right?

A Yes, sir.

Q There's lymph -- I'll garble this word, but there's lymphohematopoietic cancer; right? That's like cancer of the blood cells; right?

A Yeah. It's an old -- more old-fashioned term for blood cancers.

- Q So this is an outdated term?
- A That one term is, yes.
- Q All right. Then there's non-Hodgkin's lymphoma. We talked about that; right?

A As well as below that the non-Hodgkin's lymphoma B-cell, yes.

- Q B-cell. There's CLL. That's a form of non-Hodgkin's lymphoma; right?
 - A Yes, sir.
- Q There's diffuse large cell B-cell lymphoma. There's a form of non-Hodgkin's lymphoma; right?
 - A Yes, sir.
 - Q Marginal zone lymphoma. Is that NHL?
 - A That's a subtype of non-Hodgkin's lymphoma,

1 \parallel yes.

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

- Q Multiple myeloma. Is that a form of NHL?
- A No, sir.
 - Q It's a blood disease?
 - A It's a different type of cancer, yes.
 - Q Non-Hodgkin's lymphoma T-cell; is that right?
 - A Yes.
 - Q And acute myeloid leukemia; correct?
 - A Yes.
- Q Leukemia is a blood cancer; right? Most of the time.
- A It's a word to describe cancer circulating in the blood system, yes.
 - Q But no mantle cell?
- A Not in the specific category beyond that of non-Hodgkin's lymphoma B-cell; correct.
 - Q You can set that aside.
- You said earlier, and I thought I heard you say this, that when a study -- a study can become outdated. That how you criticized some of the studies that Dr. Aronson and Dr. DeGrandchamp relied on, that they were outdated?
- A A meta-analysis can be outdated if it's attempting to include all the available literature and then new literature emerges, that combination work is no

longer up-to-date.

2.1

Q The Zhang meta-analysis is the -- is the most recent meta-analysis in this area; right?

- A That's not true.
- O What is?

A The most recent meta-analysis would be the one by Boffetta and colleagues in 2021. But there's also the work by Leon and colleagues in 2019 that also came available after Zhang and colleagues reported theirs. And the third would be the meta-analysis performed by the EPA in the year 2020.

- Q And also an NCAP study that came out; right?
- A NCAP is a cohort study that is included within a meta-analysis performed on that in combination with a third cohort called AGRICAN, as well as the Agricultural Health Study. That was work that was done -- I think it was done by, I forget the authors. Perhaps De Roos and colleagues, but I forget the authors.
- Q And the NCAP study involved over a hundred thousand people; right?
- A I don't remember the number of patients involved in that cohort.
- Q Have you seen the Zhang study that talks about glyphosate exposure and urinary oxidative stress biomarkers in the Agricultural Health Study?

I'm not sure. If you could provide it. 1 Α 2 MR. BROWN: Thank you, sir. 3 THE WITNESS: Thank you, sir. BY MR. FRAZER: 4 5 This is a 2023 study. Do you seen that? 6 Α Yes, I have seen that. 7 0 You have seen it? 8 Α Yes, sir. 9 Q Do you see who the second named author is? Yes. It's Dr. Andreotti. 10 Α 11 Dr. Andreotti, the same one that did the 12 Agricultural Health Study that you're relying on; right? 13 Α The first author in the 2018 manuscript that 14 came from that study, yes. 15 Yeah, she's in this paper too? 16 Yes, sir. Α 17 And this paper concludes that "Our findings 18 contribute to the weight of evidence supporting an --19 supporting an association between glyphosate exposure 20 and oxidative stress in humans and may inform evaluation 21 of the carcinogenic potential of this herbicide"; 22 correct? 23

Α Yes, you've read it correctly.

24

25

Are you aware of the study published in 2023 by the first name author is Benbrook?

- 1
- A I'm not sure. Could you provide it?
- 2
- Q All right. That's P3132.
- 3
- A Thank you, sir.
- 4
- Q That study was published on January 16th, 2023, this year; right?
- 6

- A I'm looking.
- 7
- Q Down there at the bottom.
- 8
- A I see it. Yes, sir.
- 9
- Q Sometimes it's hard to find it, isn't it?
- 10
- A It is. Every journal does it differently.
- 11
- Q And the title of this is "Genotoxicity Assays
- 12
- Published since 2016 Shed New Light on the Oncogenic
- 13
- Potential of Glyphosate-Based Herbicides"; right?
- 14
- A That is the title.
- 15
- Q Okay. You've done no study of what's in a bottle of formulated Roundup Ready-to-Use; correct?
- 17

16

- A No, sir.
- 18

19

- Q You know that the Agricultural Health Study that you rely on was farmers spraying agriculturally;
- 20

2.1

right?

- A It was professional applicators, yes.
- 22
- Q Have you ever looked at the warnings that farmers get on their Roundup label?
- 23

- A No. I haven't reviewed the labels.
- 25
- Q You know that farmers using it sit up in a

tractor and they've got what are called booms that go outside the tractor and they spray the field.

Do you know that?

2.1

A What I know is that more than half of the participants in the Agricultural Health Study used no personal protective equipment in their professional role.

Q We've heard that. I'm just saying. Do you know those farmers use a boom to spray it?

They don't do it like in your little picture there and go down the crop rows with a sprayer, do they?

- A I think there's both happening.
- Q You believe that people out there spraying acre, upon acre, upon acre, you drive through Southern Illinois, you go through western Missouri, there are farmers out there spraying by hand their crops?
- A That's what they -- what the scientific published evidence is, is that there are more than half of these professional applicators that are doing so without personal protection, yes.
 - Q Okay. We hear you.

Back to my question. You don't know what's in the bottle of Roundup Ready-to-Use?

A No. I can't list the full ingredients and percentages with precision.

You don't know what carcinogens are in a 1 Q 2 bottle; right? 3 I don't know what chemicals are in a bottle. 4 Q You've not looked at any internal Monsanto 5 documents, have you? 6 No, sir. 7 You have no idea what Monsanto inside the 8 company thinks about Roundup and human cancer, do you? 9 What I know is the published scientific 10 evidence on the question. 11 So you don't have any idea what Monsanto's 12 internal scientists, they got degrees too, have said 13 about formulated Roundup? What I know is what the published scientific 14 15 literature says about formulated Roundup. 16 You know that arsenic is a carcinogen; right? 0 17 Potentially. Α 18 Arsenic's found in cigarette smoke, isn't it? Q 19 Α I'm not sure. 20 Don't even know? 0 2.1 I believe. Α 22 1,4-dioxane is a human carcinogen; right? Q 23 Α I don't know a lot about that specific 24 chemical. 25 Ethylene oxide is a human carcinogen; correct?

A There is some inconsistency but many do believe so.

And yet that's an interesting chemical, because it's one that's actually made by our bodies naturally during normal metabolism. It's an interesting example.

Q Our bodies actually make it, but our bodies don't make enough of it to kill us, right, or cause cancer?

A I'm just saying it's literally a byproduct and a lot of us are making it.

Q You know people are getting exposed to ethylene oxide from places where they are decontaminating surgery equipment, don't you?

A I believe it's used in some facilities that clean surgical equipment, yes.

Q Yeah. And the EPA is looking into that, and you know about the EPA; right?

A Yes, I know about the EPA.

Q Okay. Formaldehyde is a -- is a human carcinogen. We can agree on that, can't we?

A We can, yes.

Q Do you know it's in a bottle of Roundup?

A I don't know either way.

Q Have you ever heard of a substance called NNG?

- 1
- A Not that I know of.
- 2
- Q How about NNN?
- 3
- A Not that I know of.
- 4
- Q Do you know whether or not cigarettes have N-nitro salines in them, cigarette smoke?
- 5
- A No, I do not.
- 7
- Q Have you heard of a chemical with the acronym AMPA, A-M-P-A?
- 8
- A I believe so.
- 10
- Q That's a known carcinogen; right?
- 11
- A I'm not sure.
- 12
- Q Have you looked at any dermal studies that Monsanto did to see if glyphosate or formulated Roundup
- 14

- could get into human beings' skin?
- 15
- A No. Again, I've looked at the published scientific literature.
- 16

17

- Q Have you seen the studies of the Mexican
- 18
- children in villages in Mexico that have been sprayed

with glyphosate and that every child in the village has

19

20

glyphosate in their urine?

Q

- 21
- A I'm not sure which paper you're referring to.
- 22
- A I said I'm not sure.

You never read that?

- 23
- Q Have you read the CDC study on glyphosate in
- 25

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 2.1
- 22
- 23
- 24
- 25

- I'm not sure. Α
- Would you agree that randomness is random? Q
- That's a funny question. Α
- Q It is a funny question; right? I mean, randomness is by definition random?
 - I can't argue with that. It's a truism.
- You're not aware of a single scientific organization in the whole wide world that classifies randomness as a risk factor for any cancer; right?
- We don't think about it in those terms. a matter of understanding the actual cause of cancer. One doesn't talk about the way our systems are built as a risk factor. In this case it's just the reason why.
- Well, Dr. Tomasetti, your opinion of randomness is what causes the cancer; right?
 - Α Sorry.
- That's the biggest risk factor that you say we have?
- You're confusing risk factors and causes. statement was that it's that replicative error that is the actual cause of the cancer.
- Okay. If randomness is randomness, then it cannot be random by definition if it's due to nothing but chance or bad luck, right.
 - I don't understand your question.

1 apologize.

2.1

Q I don't understand your testimony. Maybe that's why you don't understand my question.

MR. BROWN: Objection, your Honor.

THE COURT: Sustained.

Ask a question, Mr. Frazer.

BY MR. FRAZER:

Q The very definition of randomness is that something occurs without any explanation; right?

A Random replicative errors is specifically referring to those errors that happen during the copying of our DNA.

Q Without any explanation?

A The occurrence of it is unpredictable. That's what randomness means. We understand why these errors happen. The errors happen because our DNA copying systems, while excellent, extraordinary, are imperfect.

Q To use your phrase, when you roll the dice, whatever those dice come up with, if you roll them two, is random; right?

A Yes, rolling dice is random.

Q It's kind of circular reasoning. If something is random because it's random, therefore, it's random?

That's really what you're saying; right?

A I disagree.

Q Okay. Would it be fair to say if there was a nonprofit organization or cancer center that was collecting money to do research projects on determining the cause of non-Hodgkin's lymphoma, you would say don't give them a penny?

A Can you repeat your question?

2.1

Q If there was a nonprofit organization or medical center or pediatric cancer facility or adult cancer facility or Siteman Center that was trying to raise money to determine the cause of non-Hodgkin's lymphoma, your position and Dr. Tomasetti's position would be don't waste your money because it's all due to replication error; right?

A No, that's not true. First -- and there's a couple reasons why.

The first is that you're speaking about non-Hodgkin's lymphoma as this single clinical entity and, as I've tried to explain, that's not true. And I've given you examples today of specific types of non-Hodgkin's lymphoma that do have causes other than random replicative error.

The stomach lymphoma caused by the H. pylori bacteria. There's others. There's a form of T-cell lymphoma called ATLL. It's adult T-cell lymphotropic leukemia lymphoma. It's a mouthful. It's caused by a

specific virus called HTLV-1 that can be passed from mother to child.

2.1

We know that there are certain types of lymphomas that do have causes other than random replicative error. And preventing lymphoma remains an important mission when we can do so.

- Q Let me rephrase the question. Those are known other causes, these viruses that you mentioned, right, or bacteria?
 - A Those two examples have been established, yes.
- Q You're getting off into other subtypes that have nothing to do with John Durnell; right?
- A Your question, as I understood it, was is it worthwhile to study lymphoma, and I'm trying to give you examples of how, yes, that work has led to progress in my field by doing such research.
- Q Let me put it this way. You would think it would be a total waste of money for any cancer facility or group of people to raise money to try to determine whether or not Roundup causes cancer in human beings that is non-Hodgkin's lymphoma. That's a waste of money?
- A It's a question that already has been answered definitively by the science.
 - Q I didn't ask -- that wasn't my question. My

question is it's a waste of money to do that. In your opinion.

- A To have done that.
- Q In your opinion.

2.1

A No, I'm glad that the research was conducted. It's allowed us to be able to be here and be able to refer to the science and the evidence so that we can have consequence that in fact it's not causing lymphoma. It's particularly important research to have been conducted, and I'm grateful for it.

- Q Well, we can agree that all older white males do not get non-Hodgkin's lymphoma. I hope the answer is no, because I'm an older white male.
 - A You and me both.
 - Q I'm a lot older than you.

 But that answer is no? We all --
 - A Of course.
- Q Okay. And we all don't use Roundup either, do we?
 - A True.
- Q We can agree that people get randomly exposed to formulated Roundup every day based up those urine studies; right?
 - A I'm not sure.
 - Q Well, not everybody in America is spraying

Roundup, are they? 1 2 Α No. 3 We can agree that folks can randomly walk into 4 an Ace hardware store and randomly decide to buy a 5 gallon of Roundup Ready-to-Use; correct? 6 That wouldn't be a random decision. 7 Okay. People can use choose to randomly go 8 home and spray their property and their cracks in their sidewalks and the cracks in their driveways; right? 9 10 I think you and I are using the word "random" 11 very differently. 12 Okay. Have you seen any of the parks that 13 Mr. Durnell sprayed? I've seen the photographs that were included 14 15 in the deposition materials. 16 Did you see that there were, on some of them had children's playground equipment? 17 18 I don't remember that. 19 Have you seen any studies that Monsanto did to 20 determine how people are getting glyphosate in their 2.1 urine in America? 22 If the question, as I understand it, if I reviewed any internal studies within Monsanto, the 23 24 answer is no, I have not.

25

Have you seen any study that Monsanto did

that's -- where they paid to have an epidemiology study 1 2 done? 3 No, I haven't reviewed any Monsanto-conducted 4 research. Have you reviewed any of the Monsanto 5 6 documents on a laboratory called IBT? 7 Not that I'm aware of. 8 Have you heard of a Monsanto expert named Dr. 9 Parry? 10 Not that I'm aware of. 11 Do you know anything about Dr. Parry's recommendations to Monsanto back in 2000? 12 13 Α No. 14 Have you seen any of the documents regarding 15 the IARC decision before IARC met and after IARC met and 16 Monsanto's reaction to it? 17 Α You mean documents that would be internal to 18 Monsanto? 19 Yes, sir. 20 No, sir. Α 2.1 Have you ever met with Donna Farmer? 22 No, sir. Α 23 Have you ever met with William Heydens, Bill Q 24 Heydens? 25 Spell the last name. Α

1 Q H-e-y-d-e-n-s. 2 These are all Monsanto people. I'm sorry. 3 Α Thank you. 4 No, not that I'm aware of. 5 Q Have you met with any Monsanto employees? 6 Α Not that I'm aware of. 7 How often have you been to St. Louis in Q 8 connection with your testimony? 9 This is my first time in St. Louis with regard 10 to this testimony. 11 First time ever in St. Louis? 12 Α No. No, sir. 13 You've been here before on pleasure or 14 conferences, something like that? 15 Yeah. I like to go to different ballparks Α 16 with my dad and my brother. 17 I'm was to ask you about that. Are you a 18 Yankies or Mets guy? 19 Α Tigers. 20 Tigers. Did you grow up in Detroit? 2.1 Yes, sir, I did. Α 22 I actually got to go to the old Tiger stadium 23 one time. It was --24 It's a beautiful place. Α

-- quite a place. It was a long time ago.

3

4

5

6

7

8

9

10

11

12

13

14 15

16

17

18 19

20 2.1

22

23

24

25

So I got off on baseball. Now I'm thinking of the playoffs, so I got to -- I've got to regear here.

Have you ever looked at the EPA study as part of your analysis in this case, which was the revised glyphosate issue paper, evaluation of carcinogenic potential, EPA's Office of Pesticide Programs December 12th, 2017?

- Α Yes, sir.
- You've looked at that?
- Α Yes, sir.
- That's D25. 0

MR. FRAZER: Do we have that one?

THE COURT: Somewhere.

Do you want me to find it, Mr. Frazer?

MR. FRAZER: I've got one for the witness.

THE WITNESS: Thank you, sir.

BY MR. FRAZER:

- Is that the study we're talking about?
- I believe so.
- Let me ask you this first question. Do you see there's a bunch of studies that are attached? There's a reference page, and then there's a big long reference, study pages in the way back.

Do you see all that?

I see you showing it to me, yes. Yes, I see

references and some appendices after that.

Q Dr. Tomasetti's article doesn't appear anywhere in there, does it?

A Pardon me?

2.1

- Q Dr. Tomasetti's article does not appear anywhere in this document?
 - A Not that I'm aware of.
- Q Not his 2015 article and not his 2017 article; correct?
 - A No, it isn't.
 - Q All right. Glad we got that straight.

Do you have any idea how much glyphosate is used in the U.S. in the agricultural market as compared to the Roundup Ready-to-Use market that folks like Mr. Durnell are exposed to do?

A I haven't seen any summary statistics on that question, no.

Q Would it surprise you that it's less than 1 percent for Roundup Ready-to-Use lawn and garden products?

A It would neither surprise me or not surprise me. I just don't know.

O Don't know.

Do you know how many millions of pounds of glyphosate are used?

- A I had that slide where I had some of the EPA data regarding glyphosate use.
- Q Well, you've got it out of page 17, which is D25.21 of Defense Exhibit 25; right?
 - A Thank you for helping me find it. Yes, sir.
 - Q That's where you got it from; right?
 - A Correct.
- Q You know what happened in the early '90s in terms of genetically modified seeds and the rise of glyphosate use in the agricultural market in the U.S.?

MR. BROWN: Objection, your Honor. Beyond the scope of direct examination.

THE COURT: I'll overrule it. He can answer if he knows the answer.

THE WITNESS: I understand that there's been changes in agriculture that have generated different types of crop strains, but I'm not certain of the specifics.

BY MR. FRAZER:

- Q Well, I mean, the little exercise you did on direct, you took this chart right here; right? This is the one you used, the one at the top; am I right?
 - A Yes, sir.
- Q Or somebody took it, I don't know if you did.
 But somebody on the Monsanto team took it and then you

put another chart up that looked at the incidence of non-Hodgkin's lymphoma in the United States; right?

A Correct.

Q And what you wanted to do is put one over the other and create the appearance that look at all this big Roundup use and non-Hodgkin's lymphoma only goes up about 50 percent, it doesn't go up as high as the glyphosate use; right?

That's why you did that?

A That's a mischaracterization of the data that I shared with you. Over the two decades non-Hodgkin's lymphoma rates were flat.

Q You actually compacted it to get it even flatter; right? You compacted. You ignored your own data, didn't you?

You didn't start it back in 1987? You moved it as far as you could to get a ten-year period to make it look like it was even less of a rise of an incidence of NHL in the United States; right?

MR. BROWN: Objection. That is not accurate at all.

THE COURT: I'll say it was about five different questions. So I'm going to have you re-ask a question that he can answer.

2.1

BY MR. FRAZER: 1 2 Well, let's look at your slide. I didn't make 3 up these slides. You did; right? 4 Am I right? Yes, sir. 5 Α 6 MR. FRAZER: Something is not working here. 7 Lamp? 8 THE COURT: He's on his way. 9 BY MR. FRAZER: 10 All right. You see that? Q 11 Α Yes, sir. 12 That was your slide; right? Q 13 Α Yes. You didn't create this slide, though, do you? 14 Q 15 I modified it. I worked on it, yes, sir. Α 16 You modified it. Somebody else created it and 17 you modified it? Drafted, yes. 18 19 What did you modify in there? 20 I don't remember specifically with this slide. Α 21 Well, there are just two charts, aren't they? Q 22 Α Yes. 23 So what did you modify? Q 24 It may have just been formatting, the size of Α 25 the picture.

The size of the picture? 1 Q 2 Α Yeah. 3 That was your contribution? 4 Α Not the data. The data are drawn from 5 scientific literature. 6 Okay. Now, you know from -- you said you 7 relied on the EPA; right? You said that? 8 Α In part, yes. 9 Yeah. You know that in the EPA document, 10 Defense Exhibit 25, that glyphosate use tracked the 11 agricultural use due to the genetically modified seeds 12 that were being put out in the farm country; right? 13 You know that, don't you, sir? What I show --14 Α 15 I don't have to convince you of that? 16 What I show you here is the usage over time. Α 17 That's absolutely right. 18 And if we look -- and let's go back to D25, to 19 the map of the United States of America. 20 If we -- can you bring that up? 21 You've seen this before? 22 Yes, sir. Α 23 The rise in glyphosate use is what you would describe as farm country; right? 24 25 This doesn't show rise, but it shows estimated Α

1 use in a largely less urban center. So certainly not
2 exclusively.

- Q Sir, it literally says, "Estimated use on agricultural land in pounds per square mile"; right?
 - A Yes, sir.

2.1

- Q It doesn't say anything about Roundup
 Ready-to-Use being used in St. Louis, Missouri, in a
 place called Soulard Park, does it?
 - A No, sir.
 - Q So this is all agricultural use?
- A For this one picture that you're showing me yes.
- Q So you understand that your graph that you did, or did your editing or whatever the modification to, was a graph based upon agricultural use?
- A I have to review the data for that graph. If I can just have a moment.
 - Yes. It was agricultural use.
 - Q Agricultural land.
- So the use that was going up, so you could plot that against the NHL in the country, was agricultural use; right?
 - A Yes, sir.
- Q Yeah. It wasn't millions and millions and millions and millions of pounds of

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

glyphosate that were being used in a Roundup Ready-to-Use lawn and garden situation; right?

That's correct.

Q And let's just take the Agricultural Health Study that said approximately 50 percent of farmers never wore PPE have used glyphosate-based herbicides. We'll just accept that. Okay? We'll accept that, that there's 50 percent of all farmers never used PPE.

Okay? We'll accept that.

- Α Okay.
- 50 percent do, though; right? Q
- Α In some form or other.
- You're not aware of any PPE that Roundup Ready-to-Use lawn and garden people are told to wear, are you?
 - Α I'm not sure.
- You don't know whether the rise or nonrise of NHL in the United States of America over that period that you plotted in your slide had anything to do with Roundup Ready-to-Use users getting non-Hodgkin's lymphoma; right?
- As you just showed us, again, it's not rise or It's a completely flat rate of lymphoma in nonrise. this country.
 - Well, Dr. Tomasetti said it was a rise of

about 50 percent over a 50-year period.

Do you disagree with him?

- A And yet over the last 20 years it's been static.
 - Q The last 50 years is what we're talking about.
- A I can't quote 50-year statistics off the top of my head.
- Q Do you know how long Roundup has been on the market?
- A In some formulation or other, I think since the '70s.
- Q Since 1975. That's about 50 years ago, isn't it?
 - A Yes.
 - MR. FRAZER: That might be a good stopping place for the break, your Honor.
 - THE COURT: We'll take our afternoon break, folks.
 - Do not form or express any opinions about the case until it's given to you to decide. Don't research any issues on the case or talk to anyone about the case. We'll come back after our afternoon break.

(Recess taken.)

THE COURT: Welcome back. Once again, I'll

turn it back over to Mr. Frazer.

MR. FRAZER: Your Honor, you'll be pleased.

I've only got a few questions left, hopefully.

THE COURT: I'll believe it when I hear, Mr. Frazer.

MR. FRAZER: Well deserved, your Honor. Well deserved.

Good afternoon, ladies and gentlemen. Your Honor, may it please the Court.

THE COURT: It may.

MR. FRAZER: Learned counsel, good afternoon.
BY MR. FRAZER:

- Q And, Dr. Matasar, good afternoon again, sir.
- A Okay.
- Q I just got a few questions to try to wrap up a few things.

The graph that we saw on your slide which shows Roundup usage growing that we just talked about, the agricultural use growing, and incidence of NHL, the Roundup use growing doesn't necessarily mean that more people were using Roundup. It just means that a lot of Roundup was being used; right?

- A That's true.
- Q And over a 20-year period in this country, you would agree that the actual number of farmers, if we

believe the news these days, has gone down over time. Family farms have gone away; right?

A I listen to the news as you do, but I don't know any numbers around farming.

Q It's entirely possible that over a 50-year period in America, or just going back to 1995 when GMO seeds started coming out, that the actual people using Roundup, even in agricultural situations, has gone down.

That's possible; right?

- A Yeah, I don't know.
- Q Have you had any patients come to you who were veterans of the United States Marine Corps?
 - A Yes, sir.
- Q Who were stationed at Camp LeJeune and got cancer from drinking water at Camp LeJeune?
 - MR. BROWN: Objection, your Honor. Beyond the scope.

THE WITNESS: I do not think so.

THE COURT: He answered the question.

THE WITNESS: I haven't had any patients who

told me that they were at Camp LeJeune.

BY MR. FRAZER:

Q Have you treated any Persian Gulf Iraqi War or Afghan War veterans who were exposed to toxic substances when they were giving their service for our country?

A I have taken care of veterans who served in those war zones.

Q And have you seen non-Hodgkin's lymphoma in those veterans?

A If I'm seeing them it's because they have lymphoma, yes.

Q And is their non-Hodgkin's lymphoma part of an environmental exposure?

A I talked to those patients, as I would talk to any of my patients, try to understand their own personal risks and exposure is part of that, and I will tell patients, you know, if you had potential exposure as part of your military service, then you need to pursue appropriate remedies.

Q Yeah, like the radiation bullets that some of our service people have been exposed to; right?

A Uh-huh.

Q The fires where they had to burn all their stuff and they were exposed to whatever was toxic in the smoke; right?

A I've heard descriptions of fire pits, yes.

Q Yeah, the fires.

And in those instances, non-Hodgkin's lymphoma would have an environmental component to it; correct?

A In some cases, yes.

1	Q Now, we can agree that well, strike that.
2	I'm going to save that for last.
3	I want to look at just a couple more of your
4	slides.
5	Ed, do you have his slide show still up? This
6	is the one I'm looking for. They're not numbered.
7	THE COURT: It's down kind of on the left
8	side, real light.
9	MR. FRAZER: Wow, Judge, you have good eyes.
10	THE COURT: I was told it was there.
11	BY MR. FRAZER:
12	Q By the way, do you have a cell phone on you?
13	A I do by I think my notifications are off.
14	Q I'm not saying that.
15	Do you have a calculator on your cell phone?
16	A Yes, sir.
17	Q Would you mind pulling that out.
18	How many people are in the world?
19	The last time I looked it was 7.89 billion
20	people; is that fair?
21	A I don't know. I believe you.
22	Q You believe that, 7.89 billion?
23	Do you know how many people live in the United
24	States?
25	A It's hundreds of millions, but I don't know

the precise number.

- 2 | Q Hundreds of millions?
 - A Yes.
 - Q The figure I have is 334 million.
 - Is that fair?
 - A I believe you.
 - Q All right. I want you to do some math for us. Because in this slide you say there are 500,000 new cases of non-Hodgkin's lymphoma per year worldwide; right?
 - A Diagnosed and contained within registries, yes.
 - Q That's your number?
 - A Yes, sir.
 - Q On your slide; right?
 - A Yes, sir.
 - Q And then you say there are 80,550 new cases of non-Hodgkin's lymphoma in the United States of America every year?
 - A Diagnosed and contained within our registries, yes.
 - Q All right. Tell us, use your calculator, unless you -- you might be like Dr. Tomasetti and be able to do this in your head. I don't know. I don't want to -- I couldn't do it.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20 2.1

22

23

24

25

But what percentage of the 500,000 cases worldwide are the 80,550 new cases of non-Hodgkin's lymphoma in the United States?

So I could do the math in terms of those cases that are diagnosed and tracked in available cancer registries.

The math, you take the small number and divide the big number into it; right? I think I remember that from high school.

No, it's the small over the small plus the big. No, that is probably contained within -- so small over the big. Yeah.

It's 16.1 percent.

16.1 percent. Q

So the U.S. has 16.1 percent of all new non-Hodgkin's lymphoma cases worldwide; right?

That are diagnosed and tracked within Α available cancer registries, yes.

Okay. Now, if we take the worldwide population, I'll represent to you it's 7.89 billion.

Can you do this on your math?

I'll try. Α

What is the U.S. population as a percentage of the worldwide population.

You said it was 300? Α

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1 22

23

24

25

334 is what I wrote down from Google Scholar, Q to use Dr. Tomasetti's term.

Google Scholar is a wonderful tool.

And you said the global population you wanted me to use was?

7.89 billion. 0

My little calculator gives me approximately 4.2 percent.

4.2 percent?

Α Yes.

So the U.S. population as a total of the world population is 4.2 percent, but the U.S., the U.S. has 16.1 percent of all non-Hodgkin's lymphoma in the world?

No.

No? 0

No. Α

That's on your list right here.

And I've clarified each time you asked to say for the diagnoses that are contained in cancer The world has a lot of the countries in it registries. that track their cancer diagnoses incidence data very differently.

So this is the available public data, but it's not in any way believed to be a representation of the total lymphoma in the world.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

25

So you're being critical of the own data that Q Is that what you're telling this jury? you use?

I'm telling you that there's limitations to it. Absolutely right.

Every scientist has to understand the flaws of their own data.

If your data is correct as we see on this slide, we've got a worldwide percentage population of 4.1 percent in the U.S. and we've got 16.1 percent of non-Hodgkin's lymphoma; right?

- Α Yeah.
- If your numbers are right?
- Α That's how that math works, yes.

Okay. All right. Let's look at -- I can't see the number on this. There we go. Actually do the ELMO on this one.

I'll show the slide. Show the slide real quickly, because I want them to see it without --

This was a slide that you put up on how cancer happens; right?

- To try to describe that, yes.
- Let's switch to the ELMO, please. Q

You see my little green highlight there? It's not very fancy, but it's there.

I don't. Can you help me?

- 1
- Q Right here.
- 2
- The green one? Α
- 3
- You see that? Q
- 4
- Α Yes, sir.
- 5

- Q That's where -- that's the moment before mutation occurs; right?
- 7
- As shown in this cartoon, yes.
- 8 Q And if we were putting glyphosate in a cell,
- 9
- 10 it under the microscope and it caused a mutation, you
- 11
- would see that drop of glyphosate fall into the petri

scientific evidence that glyphosate causes mutations

glyphosate or formulated Roundup on an animal cell that

over the world that when they dropped a drop of

You don't doubt that, do you?

they observed a mutation under a microscope?

dish and we would see a mutation that would occur next;

For me, that falsely assumes that there's

You don't doubt cell studies by scientists all

an animal cell, a sea urchin study, and we're looking at

- 12
- 13 right?
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- You do? Q

Α

Yes, I do.

that lead to cancer.

There's evidence of genotoxicity of that cell, Α 25 of the DNA damage, but not evidence that it causes

mutations that can lead to cancer.

1

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

- 2 Q So these scientists just made that up?
 - A I disagree with your interpretation of their work.
 - Q All right. We can agree -- oh, one more thing. Show you one study I forgot to show you earlier.
 - A Thank you.
 - Q My question to you is have you seen this study before?
 - A No, I have not, sir.
 - Q You haven't seen this one?
 - A No, sir.
 - Q It's by the same Gabriella Andreotti, a study that you're relying on?
 - A It's by the same author that was the lead author in one of the manuscripts I shared today, yes.
 - Q Got Aaron Blair's name in it?
 - A I see that.
 - Q Got a guy named Charles Lynch. He's with the EPA?
 - A I see that.
 - Q And the title of it is Occupational Pesticide
 Use and Risk of Renal Cell Carcinoma in the Agricultural
 Health Study; right?
 - A I see that.

And the date that this was published was June 1 Q 2 12th, 2020, down there at the left? 3 I see that as well. 4 Q Thank you, sir. 5 We agree that for decades that the tobacco 6 industry said cigarette smoking doesn't cause cancer; 7 right? 8 Yes, sir. 9 The tobacco companies said don't look at 10 animal studies at all because animals aren't people; 11 right? 12 I don't know what their positions were, to be 13 honest. 14 The tobacco companies --MR. BROWN: Your Honor, if we may approach 15 16 briefly. 17 Sorry to interrupt, Counsel. 18 (Counsel approached the bench and the 19 following proceedings were had:) 20 THE COURT: Who am I getting argument from? 2.1 Hold on. Ms. Cook? 22 MS. COOK: Yes. 23 THE COURT: Ms. Cook. 24 MS. COOK: We have an agreed motion in limine, 25 D26, to references to the tobacco industry that Mr.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

2.1

22

23

24

25

Frazer just violated.

So we would request that his testimony -- by what I mean is his questions that were testimony be stricken and that the jury be asked to disregard.

MR. FRAZER: They talked about on direct, they talked about cigarette smoking at length and lung cancer.

MS. COOK: The motion is on the tobacco industry.

MR. FRAZER: That's who makes cigarettes.

THE COURT: Here's what I'll say. I won't strike the questions. I'll let the question stand, but based on your agreed-to motion in limine, and I know this might be your grand finale, but I'll ask you to move on, and leave the answers stand as they are.

MS. COOK: Thank you.

(Proceedings resumed in open court.)

BY MR. FRAZER:

It would be fair to say that every study in the scientific literature that Monsanto does not like in what it says about glyphosate and/or about Roundup formulated, those are the studies you've thrown out of your analysis?

I don't think about things in terms of who

likes or doesn't like science. I look at the science based on the quality of the conducted research, and I've tried to be as clear and explicit as to my methodology and to how I evaluate the quality of the science with you here today.

2.1

Q Those are the studies you've thrown out, every study that Dr. Aronson and Dr. DeGrandchamp and Dr. Spaeth relied upon; right?

A I don't throw out studies. I evaluate studies. And I pointed out some of the challenges with the earlier research that limit their reliability.

Q You've thrown out the entire IARC report and findings that glyphosate is a probable human carcinogen; correct?

A I don't throw out anything, neither papers nor monographs. I performed a weight-of-the-evidence analysis, including looking at IARC's review, as have many others, including the EPA and other regulatory agencies arriving at the same conclusion.

Q You threw out the 96 scientists letter that came out in support of the IARC finding of glyphosate as a probable human carcinogen; correct, sir?

A I still say that I don't throw anything out.

I evaluate the science and I arrive at scientific conclusion.

Have you ever heard of a saying by a famous Q Missourian named Mark Twain about lies? You'll have to refresh me. Do you remember that Mark Twain said there are three kinds of lies? I do know this one. Lies, damn lies, and statistics; right? Yes. Α MR. BROWN: Your Honor, objection. THE COURT: It's been asked and answered. Do you have anything else, Mr. Frazer? MR. FRAZER: No further questions.